ID   Mel285
AC   CVCL_C303
SY   MEL285; Mel-285; Mel 285
DR   cancercelllines; CVCL_C303
DR   Cell_Model_Passport; SIDM01793
DR   Cosmic; 916140
DR   Cosmic; 1628405
DR   Cosmic; 2036708
DR   DepMap; ACH-002015
DR   Wikidata; Q54905164
RX   PubMed=16772116;
RX   PubMed=22236444;
RX   PubMed=22383533;
RX   PubMed=23849826;
RX   PubMed=28018010;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   From: Ksander, Bruce R.; Schepens Eye Research Institute; Boston; USA.
CC   Derived from site: In situ; Eye, uvea; UBERON=UBERON_0001768.
ST   Source(s): DepMap=ACH-002015; PubMed=22236444
ST   Amelogenin: X
ST   CSF1PO: 10,13
ST   D13S317: 11
ST   D16S539: 11,14
ST   D18S51: 16,17
ST   D21S11: 29
ST   D3S1358: 15,17
ST   D5S818: 13
ST   D7S820: 8,13
ST   D8S1179: 11,15
ST   FGA: 20,22
ST   Penta D: 5
ST   Penta E: 17
ST   TH01: 8,9.3
ST   TPOX: 11
ST   vWA: 19
DI   NCIt; C7712; Uveal melanoma
DI   ORDO; Orphanet_39044; Uveal melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 10-09-24; Version: 17
//
RX   PubMed=16772116; DOI=10.1016/j.cancergencyto.2005.11.016;
RA   White J.S., Becker R.L., McLean I.W., Director-Myska A.E., Nath J.;
RT   "Molecular cytogenetic evaluation of 10 uveal melanoma cell lines.";
RL   Cancer Genet. Cytogenet. 168:11-21(2006).
//
RX   PubMed=22236444; DOI=10.1111/j.1755-148X.2012.00971.x; PMCID=PMC3288394;
RA   Griewank K.G., Yu X.-X., Khalili J.S., Sozen M.M., Stempke-Hale K.,
RA   Bernatchez C., Wardell S., Bastian B.C., Woodman S.E.;
RT   "Genetic and molecular characterization of uveal melanoma cell
RT   lines.";
RL   Pigment Cell Melanoma Res. 25:182-187(2012).
//
RX   PubMed=22383533; DOI=10.1158/1535-7163.MCT-11-0676;
RA   Dutton-Regester K., Irwin D., Hunt P., Aoude L.G., Tembe V.,
RA   Pupo G.M., Lanagan C., Carter C.D., O'Connor L., O'Rourke M.,
RA   Scolyer R.A., Mann G.J., Schmidt C.W., Herington A., Hayward N.K.;
RT   "A high-throughput panel for identifying clinically relevant mutation
RT   profiles in melanoma.";
RL   Mol. Cancer Ther. 11:888-897(2012).
//
RX   PubMed=23849826; DOI=10.1016/j.ejca.2013.06.011;
RA   Amaro A., Mirisola V., Angelini G., Musso A., Tosetti F.I.,
RA   Esposito A.I., Perri P., Lanza F.B., Nasciuti F., Mosci C., Puzone R.,
RA   Salvi S., Truini M., Poggi A., Pfeffer U.;
RT   "Evidence of epidermal growth factor receptor expression in uveal
RT   melanoma: inhibition of epidermal growth factor-mediated signalling
RT   by gefitinib and cetuximab triggered antibody-dependent cellular
RT   cytotoxicity.";
RL   Eur. J. Cancer 49:3353-3365(2013).
//
RX   PubMed=28018010; PMCID=PMC5161001;
RA   Jager M.J., Bermudez Magner J.A., Ksander B.R., Dubovy S.R.;
RT   "Uveal melanoma cell lines: where do they come from? (an American
RT   Ophthalmological Society thesis).";
RL   Trans. Am. Ophthalmol. Soc. 114:T5-T5(2016).
//